-1768251303313.webp&w=3840&q=75)
2025 MaTOS Lung | Session IX | Targeted Therapy Forum-Part I Case-Based Panel Discussion
Overview
Case 1, presented by Dr. Le, reviewed a 45-year-old with EGFR-mutant lung adenocarcinoma, rapid metastatic relapse, initial osimertinib response, later progression, and challenges managing liver metastases and toxicity.
The panel discussed Case 2, presented by Dr. Riess, a 75-year-old with metastatic EGFR G719S NSCLC and brain mets, favoring afatinib for best PFS, chemo-osimertinib for CNS disease, and trials for rare EGFR variants.
Case 3, presented by Dr. Piotrowska, reviewed a 35-year-old woman with ALK-positive lung adenocarcinoma. Panel favored first-line lorlatinib for strong efficacy and CNS control; patient responding well.
Dr. Rotow presented Case 4, a 72-year-old with ALK-positive lung cancer developing resistance to alectinib and later lorlatinib. Post-lorlatinib progression highlighted need for rebiopsy, MET targeting, and trials.
Dr. Elamin’s Case 5, highlighted a 55-year-old never-smoker with mucinous adenocarcinoma and high PD-L1. RNA-based NGS uncovered an NRG1 fusion after progression, stressing need for RNA testing and novel drivers.
The panel discussed Case 2, presented by Dr. Riess, a 75-year-old with metastatic EGFR G719S NSCLC and brain mets, favoring afatinib for best PFS, chemo-osimertinib for CNS disease, and trials for rare EGFR variants.
Case 3, presented by Dr. Piotrowska, reviewed a 35-year-old woman with ALK-positive lung adenocarcinoma. Panel favored first-line lorlatinib for strong efficacy and CNS control; patient responding well.
Dr. Rotow presented Case 4, a 72-year-old with ALK-positive lung cancer developing resistance to alectinib and later lorlatinib. Post-lorlatinib progression highlighted need for rebiopsy, MET targeting, and trials.
Dr. Elamin’s Case 5, highlighted a 55-year-old never-smoker with mucinous adenocarcinoma and high PD-L1. RNA-based NGS uncovered an NRG1 fusion after progression, stressing need for RNA testing and novel drivers.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Christine M. Lovly, MD, PhD
Speakers and Panelists:
Xiuning Le, MD, PhD
Jonathan W. Riess, MD, MS
Jessica J. Lin, MD – Presented by Zofia Piotrowska, MD
Julia Rotow, MD
Yasir Y. Elamin, MD
Panelists:
Fred R. Hirsch, MD, PhD, FASCO
John Heymach, MD, PhD
Jeffrey Bradley, MD
Date of Release
January 9th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)